Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1984 2
1985 6
1986 22
1987 11
1988 12
1989 14
1990 12
1991 19
1992 25
1993 16
1994 17
1995 24
1996 20
1997 26
1998 25
1999 21
2000 18
2001 17
2002 24
2003 17
2004 25
2005 17
2006 19
2007 34
2008 22
2009 20
2010 11
2011 14
2012 12
2013 13
2014 12
2015 11
2016 10
2017 10
2018 12
2019 9
2020 10
2021 16
2022 14
2023 10
2024 16
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

631 results

Results by year

Filters applied: . Clear all
Page 1
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, Consiglio A, Raya A, Polgreen PM, Narayanan NS, Yuan Y, Chen Z, Su W, Han Y, Zhao C, Gao L, Ji X, Welsh MJ, Liu L. Cai R, et al. J Clin Invest. 2019 Oct 1;129(10):4539-4549. doi: 10.1172/JCI129987. J Clin Invest. 2019. PMID: 31524631 Free PMC article.
Impaired energy metabolism and reduced ATP levels are common features of PD. Previous studies revealed that terazosin (TZ) enhances the activity of phosphoglycerate kinase 1 (PGK1), thereby stimulating glycolysis and increasing cellular ATP levels. ...We found slowe …
Impaired energy metabolism and reduced ATP levels are common features of PD. Previous studies revealed that terazosin (TZ) enh …
[Terazosin].
Schäfers RF, Michel MC. Schäfers RF, et al. Dtsch Med Wochenschr. 1998 Apr 9;123(15):459-60. doi: 10.1055/s-0029-1233226. Dtsch Med Wochenschr. 1998. PMID: 9581161 Review. German. No abstract available.
Pharmacology of terazosin.
Kyncl JJ. Kyncl JJ. Am J Med. 1986 May 23;80(5B):12-9. doi: 10.1016/0002-9343(86)90846-6. Am J Med. 1986. PMID: 2872801
Terazosin is a quinazoline antihypertensive agent that is chemically similar to prazosin. ...The absorption of terazosin appeared to be slower than that of prazosin in rats. However, from eight to 16 hours after dosing, terazosin concentrations in plasma exce …
Terazosin is a quinazoline antihypertensive agent that is chemically similar to prazosin. ...The absorption of terazosin appea …
Terazosin for hypertension.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 1987 Dec 18;29(755):112-3. Med Lett Drugs Ther. 1987. PMID: 2891021 Clinical Trial. No abstract available.
Drugs for hypertension.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 May 18;62(1598):73-80. Med Lett Drugs Ther. 2020. PMID: 32555118 No abstract available.
Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders.
Liu J, Zhao W, Li C, Wu T, Han L, Hu Z, Li X, Zhou J, Chen X. Liu J, et al. Int J Mol Sci. 2021 Dec 30;23(1):416. doi: 10.3390/ijms23010416. Int J Mol Sci. 2021. PMID: 35008842 Free PMC article.
The current study was designed to explore the anti-oxidation, anti-inflammation, anti-cell death properties of terazosin, an alpha-adrenergic receptor antagonist, in vivo and in vitro. Our results indicate that terazosin dramatically activates Pgk1, and upregulates …
The current study was designed to explore the anti-oxidation, anti-inflammation, anti-cell death properties of terazosin, an alpha-ad …
Terazosin Analogs Targeting Pgk1 as Neuroprotective Agents: Design, Synthesis, and Evaluation.
Wang Y, Qian S, Zhao F, Wang Y, Li J. Wang Y, et al. Front Chem. 2022 Jul 26;10:906974. doi: 10.3389/fchem.2022.906974. eCollection 2022. Front Chem. 2022. PMID: 35958233 Free PMC article.
Nitrogen-containing heterocyclic compounds have shown promising therapeutic effects in a variety of inflammatory and neurodegenerative diseases. Recently, terazosin (TZ), a heterocyclic compound with a quinazoline core, was found to combine with phosphoglycerol kinase 1 (P …
Nitrogen-containing heterocyclic compounds have shown promising therapeutic effects in a variety of inflammatory and neurodegenerative disea …
Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men.
Hart A, Aldridge G, Zhang Q, Narayanan NS, Simmering JE. Hart A, et al. Neurology. 2024 Jul 23;103(2):e209570. doi: 10.1212/WNL.0000000000209570. Epub 2024 Jun 19. Neurology. 2024. PMID: 38896813
BACKGROUND AND OBJECTIVES: Terazosin, doxazosin, and alfuzosin (Tz/Dz/Az) are alpha-1 adrenergic receptor antagonists that also bind to and activate a key adenosine triphosphate (ATP)-producing enzyme in glycolysis. ...
BACKGROUND AND OBJECTIVES: Terazosin, doxazosin, and alfuzosin (Tz/Dz/Az) are alpha-1 adrenergic receptor antagonists that also bind …
Terazosin attenuates abdominal aortic aneurysm formation by downregulating Peg3 expression to inhibit vascular smooth muscle cell apoptosis and senescence.
Wei X, Li Y, Jiang T, Luo P, Dai Y, Wang Q, Xu M, Yan J, Li Y, Gao J, Liu L, Zhang C, Liu Y. Wei X, et al. Eur J Pharmacol. 2024 Apr 5;968:176397. doi: 10.1016/j.ejphar.2024.176397. Epub 2024 Feb 7. Eur J Pharmacol. 2024. PMID: 38331337 Free article.
Despite the severity of AAA, effective drugs for treatment are scarce. At low doses, terazosin (TZ) exerts antiapoptotic and anti-inflammatory effects in several diseases, but its potential to protect against AAA remains unexplored. ...
Despite the severity of AAA, effective drugs for treatment are scarce. At low doses, terazosin (TZ) exerts antiapoptotic and anti-inf …
Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
Wilde MI, Fitton A, Sorkin EM. Wilde MI, et al. Drugs Aging. 1993 May-Jun;3(3):258-77. doi: 10.2165/00002512-199303030-00007. Drugs Aging. 1993. PMID: 7686794 Review.
The efficacy of terazosin is reflected in increases in peak urinary flow rate, and reductions in obstructive and irritative symptom scores compared with placebo, and reductions in residual urinary volume from baseline. ...Terazosin also shows promise as a nonsurgica …
The efficacy of terazosin is reflected in increases in peak urinary flow rate, and reductions in obstructive and irritative symptom s …
631 results